Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Spotlight DK |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
COPENHAGEN, Denmark, 25 August 2025 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the second quarter (Q2) of 2025. The Q2-2025 report is available as an attached document to this press release and at www.dancann.com.
Summary: Group Key Figures Q2-2025
| DKK 1,000 | 01/04/25 - 30/06/25 | 01/04/24 - 30/06/24 | 01/01/25 - 30/06/25 | 01/01/24 - 30/06/24 |
| Net Sales | 1,182 | 3,856 | 1,427 | 4,551 |
| EBITDA | -2,236 | 228 | -4,713 | -2,175 |
| Operating profit/loss (EBIT) | -2,735 | -274 | -5,711 | -3,182 |
| Result per share (DKK) | -0.6937 | -0.0008 | -1.4651 | -0.0018 |
| Equity ratio | 0.66 | 0.32 | 0.66 | 0.32 |
Number of Shares 30.06.2025 - 3,991,052 (166,626,687)
Result per share = Result for the period / weighted average number of shares
Equity ratio = Equity / Total assets
Highlights from Q2-2025:
· Continued competitive pressure on Bedrocan® and Bediol®.
· Bedrolite® and Bedrobinol® added to the portfolio (first contributions expected in Q3).
· Divestment of Biotech Pharm1 (BP1) in its final stage.
Chairman of the Board, Carsten Trads, comments:
"The second quarter was marked by continued pressure on both price and volume, particularly within Bedrocan® and Bediol®, which affected overall performance. These competitive dynamics remain challenging, and while our strategic initiatives are underway to address them, we do not expect material impact until 2026.
That said, the third quarter has begun on a more encouraging note from a sales perspective. Importantly, Q3 is also expected to be the first quarter in which we can track the contribution from our two new products, Bedrobinol® and Bedrolite® - representing an important milestone in broadening our portfolio and strengthening our commercial foundation.
At the same time, the planned divestment of our production facility, Biotech Pharm1 (BP1), continues to progress as scheduled. The transaction is now in its final stage, with the concluding due diligence process ongoing. This step will enable us to sharpen our strategic focus and redeploy resources towards the areas where we see the strongest potential for long-term growth.
Looking ahead, we remain committed to executing with discipline and a clear focus on building sustainable competitiveness. While near-term challenges persist, we are confident that the measures being implemented today will support profitable growth and create lasting value for our shareholders."
For further information, please contact:
Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
About DanCann Pharma A/S
DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.
DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.
For more information, please visit: www.dancann.com
Forward-looking-statement:
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.
Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.
Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
This disclosure contains information that DanCann Pharma A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-08-2025.